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The aim of this study was to assess whether adjuvant treatment of breast cancer (BC) affects the risk of stroke, and to explore
radiation targets and fraction doses regarding risk and location of stroke. In a Swedish BC cohort diagnosed during 1970–2003, we
carried out a nested case–control study of stroke after BC, with relevant details extracted from medical records. The odds ratio (OR)
for radiotherapy (RT) vs that of no RT did not differ between cases and controls (OR¼0.85; confidence interval, CI¼0.6–1.3).
Radiotherapy to internal mammary chain (IMC) and supraclavicular (SCL) lymph nodes vs that of no RT was associated with a higher,
although not statistically significant, risk of stroke (OR¼1.3; CI¼0.8–2.2). In a pooled analysis, RT to IMC and SCL vs the pooled
group of no RT and RT to breast/chest wall/axilla (but not IMC and SCL), showed a significant increase of stroke (OR¼1.8;
CI¼1.1–2.8). There were no associations between cancer laterality, targets of RT, and location of stroke. The radiation targets, IMC
and SCL, showed a statistically significant trend for an increased risk of stroke with daily fraction dose. Our finding of a target-specific
increased risk of stroke and a dose-response relationship for daily fraction dose, indicate that there may be a causal link between RT
to the IMC and SCL and risk of stroke.
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Randomised clinical trials (Overgaard et al, 1997, 1999; Ragaz et al,
1997) and meta-analyses by the Early Breast Cancer Trialists’
Collaborative Group (Clarke et al, 2005) have shown a benefit of
post-operative radiotherapy (RT) in breast cancer (BC), by
reducing local recurrences and BC deaths. On the other hand,
there seems to be an excess of vascular deaths in women who were
given RT (Clarke et al, 2005). Radiotherapy to the supraclavicular
(SCL) lymph nodes includes the proximal part of the carotid artery
in the photon field. Studies of head and neck cancer have shown an
increased risk of carotid stenosis, followed by ischaemic stroke
after RT (Cheng et al, 2000; Dorresteijn et al, 2002; Haynes et al,
2002).
Our earlier study (Nilsson et al, 2005) showed a statistically
significant increase of 12% of stroke in a large BC cohort. Another
study (Jagsi et al, 2006) found similar results, whereas two others
did not (Hooning et al, 2006; Woodward et al, 2006). None of the
last three studies showed a statistically significant increase of
stroke among women given RT to the SCL.
In our case–control study, we aimed to assess whether any
adjuvant treatment of BC, such as RT, tamoxifen, and chemo-
therapy, affects the risk of stroke, and to explore radiation
targets and radiation fraction doses regarding risk and location
of stroke.
PATIENTS AND METHODS
We conducted a case–control study of the first stroke after BC
nested in a cohort of women with BC. The cohort comprises 4689
women with a first invasive BC diagnosed during 1970–2003
residing in Uppsala County, Sweden, at diagnosis and registered in
the Swedish Cancer Register, which has 98% coverage (Mattsson
and Wallgren, 1984). To identify stroke after BC, the cohort was
linked, by Personal Registration Numbers, to the Swedish Hospital
Discharge Register, containing all in-patient health care events.
The definition of stroke was based on the International Classifica-
tion of Disease (ICD) codes (Table 1). The ICD codes were grouped
into the following subtypes: ischaemic stroke, cerebral haemor-
rhage, and ill-defined cerebrovascular lesion (Lawlor et al, 2002).
We found 316 eligible women with an invasive BC followed by
hospitalisation for a stroke during the period 1970–2003, of whom
34 were excluded after record review, leaving 282 cases for
analysis. The exclusion criteria were that a stroke could not be
verified in the medical records, or that the medical records
revealed a history of stroke also before the BC diagnosis. A total of
12 women were excluded, as they did not have an invasive BC, or
as their BC was diagnosed before 1970.
For each case, one control was chosen by incidence density
sampling (Rothman, 1998) ensuring that the probability of being
chosen is proportional to the time at risk in the cohort. The control
was sampled at random, among those who were alive and without
a history of hospitalisation for a stroke at the date of the stroke, for
the case. We refer to this date as index date for the controls. Cases Revised 17 November 2008; accepted 5 January 2009
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found a stroke diagnosis in two primarily selected controls before
the index date. These patients were not in the risk set and,
consequently, were not eligible as controls. In addition, 11 controls
had no BC, or had BC diagnosed before 1970. For the 13 women,
new controls were selected for each respective case by the same
statistical method, leaving a total of 282 controls.
From the medical records we obtained information on BC,
according to the International Union Against Cancer (UICC) TNM
classification (6th edn) (tumour size, node status, presence of
distant metastases, and laterality), and details of treatments.
With regard to RT, we collected information from the chart
about target areas: remaining breast tissues after breast conserving
surgery (BCS), chest wall after mastectomy, lymph nodes in the
axilla, internal mammary chain (IMC), and SCL area. Data
regarding daily fraction radiation doses and total doses were also
collected. In respect of exposure to radiation, the subjects were
separated into three groups: (1) no RT; (2) RT to breast/chest wall/
axilla, but not to IMC/SCL; and (3) RT to IMC/SCL, irrespective of
RT to other targets. In the following, we refer to these groups as:
(1) ‘No RT’; (2) ‘RT except IMC/SCL’; and (3) ‘RT to IMC/SCL’.
During the study period 1970–2003, several different RT
regimens have been used. The thoracic wall has been treated with
low energy electrons during the whole period. The fraction
schemes were: 3Gy 15¼45Gy (1970–1985), 2.3Gy 20¼46Gy
(1986–1996), and thereafter 2Gy 25¼50Gy. Breast conserving
surgery was started in the year of 1982 in our health care region.
The remaining breast tissues were then treated with two opposed
tangential photon fields 2Gy 27¼54Gy. From 1997 and further,
the fractionation scheme was 2Gy 25¼50Gy.
The lymph nodes have been treated with different techniques
and fractionation during this period. In the period 1970–1972,
small–sized frontal Cobolt-60 photon fields to cover the SCL and
IMC were given. One such small field of 7Gy was given each day,
and in consecutive days a chain of fields were given to cover the
targets. The axilla was treated with photons (Cobolt-60), 4Gy 7
in a frontal field and 4Gy 6 in a dorsal field. In the period
1973–1976, IMC, SCL, and axilla were treated with a frontal
Cobolt-60 photon field of 4Gy 10¼40Gy. The IMCs were
treated simultaneously using a frontal field of electrons
3Gy 5¼15Gy, whereas the axilla was given 4Gy 4–5¼20–
24Gy in a dorsal photon field.
In the period 1977–1985, IMC, SCL, and axilla were treated using
a frontal Cobolt-60 photon field of 3.5Gy 9¼31.5Gy.
The IMC and SCL were treated simultaneously using a frontal
field of electrons 3Gy 5¼15Gy, whereas the axilla was
given 4Gy 6¼24Gy in a dorsal photon field. In the 1986–1994
period, IMC, SCL, and axilla were treated using a frontal photon field
of 2.5Gy 12¼30Gy. The IMC and SCL were treated simulta-
neously using a frontal field of electrons 2.5Gy 8¼20Gy, whereas
the axilla was given 3.2Gy 8¼25.6Gy in a dorsal photon field.
In 1995 and after, treatment of the lymph nodes was dose
planned, and all the included nodes were given 2Gy 27¼54Gy.
In 1997 and later, the nodes were given 2Gy 25¼50Gy.
Information regarding adjuvant endocrine treatment (specified
as tamoxifen or aromatase inhibitor), chemotherapy data (type of
regimens and number of courses), and recurrences (local or
distant) were abstracted from the medical records. For our stroke
classification, we used all available information in the medical
records, namely, medical history including clinical presentation,
results of computed tomography (CT) scan and MRI, angiography,
surgery reports, and autopsy records. We reviewed the records to
decide whether the stroke was in the vertebrobasilar or carotid
territories (Bamford et al, 1991). For carotid strokes, we also
registered left or right hemisphere location. In the 32 cases, in
which the classification and location was not obvious, two
independent reviewers carried out a consensus evaluation, but
this was still not possible in five of the cases. We registered the
presence of atrial fibrillation, documented by electrocardiography,
at the time of stroke among the cases.
Odds ratios (ORs) with 95% confidence intervals (CIs), in
the 1:1 matched case–control study, were calculated using
conditional logistic regression (Breslow and Day, 1980), adjusting
for age in four categories (o60, 60–69, 70–79, and 80þ years) at
Table 1 ICD codes and definition of subtypes of stroke
ICD 8 (1970–1986) ICD 9 (1987–1996) ICD 10 (1997–2000)
Ischaemic stroke
432 Occlusion of pre-cerebral arteries 433 Occlusion and stenosis of pre-cerebral
arteries
G45 Transient cerebral ischaemic attacks and
related syndromes
433 Cerebral thrombosis 434 Occlusion of cerebral arteries G46 Vascular syndromes of brain in
cerebrovascular diseases
434 Cerebral embolism 435 Transient cerebral ischaemia I63 Cerebral infarction
435 Transient cerebral ischaemia
437 Generalised ischaemic cerebrovascular
disease
Cerebral haemorrhage
430 Subarachnoid haemorrhage 430 Subarachnoid haemorrhage I60 Subarachnoid haemorrhage
431 Cerebral haemorrhage 431 Intracerebral haemorrhage I61 Intracerebral haemorrhage
432 Other and unspecified intracranial
haemorrhage
I62 Other non-traumatic intracranial
haemorrhage
Ill-defined cerebrovascular lesion
344 Other cerebral paralysis 344 Other paralytic syndromes I64 Stroke, not specified as haemorrhage or
infarction
436 Acute but ill-defined cerebrovascular
disease
436 Acute but ill-defined cerebrovascular
disease
I65 Occlusion and stenosis of pre-cerebral
arteries, not resulting in cerebral infarction
438 Other and ill-defined cerebrovascular
disease
437 Other and ill-defined cerebrovascular
disease
I66 Occlusion and stenosis of cerebral arteries,
not resulting in cerebral infarction
438 Late effects of cerebrovascular disease I67 Other cerebrovascular diseases
I69 Sequelae of cerebrovascular disease
ICD¼International Classification of Disease.
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of independence between laterality of BC and stroke for various RT
regimens were carried out using Fisher’s exact test. All statistical
analyses were carried out using the statistical program package
R (Ihaka, 1996).
RESULTS
The characteristics of cases and controls are described in Table 2.
Cases were significantly older. The mean age at BC diagnosis was
71.5 years (s.d., 11.0 years) for cases and 58.7 years (s.d., 13.2
years) for controls. The median follow-up period was 6.2 years
(25th percentile 2.8 years; 75th percentile 11.0 years) for cases and
5.5 years (25th percentile 1.9 years; 75th percentile 9.3 years) for
controls.
The cases had slightly more advanced cancers than the controls.
Stage I cancer was more common among the controls. Only 1% of
all subjects had distant metastasis at BC diagnosis with no
difference between cases and controls. Less than 10% of the cases
and controls had distant metastasis at the time of stroke or at the
index date (controls). Furthermore, o5% of subjects had local
recurrences at the time of stroke or at the index date. Cases and
controls did not differ regarding incidence of local or distant
recurrences.
Only four cases developed other cancers before their stroke,
whereas controls did not. The cancers were non-Hodgkin
lymphoma, ovarian cancer, small intestinal carcinoid tumour,
and gastric cancer, respectively.
Almost 80% of the strokes originated in the carotid arteries and
20% in the vertebrobasilar system (Table 3). Computed tomo-
graphy of the brain was carried out in 73% of the cases. Of these
cases, 62% had ischaemic stroke, of which 48% had cerebral
infarction and 14% had transient cerebral ischaemia. Ten percent
of the cases had haemorrhagic stroke (2%, subarachnoidal
haemorrhage and 8%, intracerebral haemorrhage). Of these cases,
28% had ill-defined stroke, mostly diagnosed in ‘the pre computer
tomography era’, and 22% of the cases had atrial fibrillation at the
time of their stroke.
We evaluated the relationship between stroke after BC and
adjuvant treatments (Table 4). In the first analysis, not adjusted for
age, we found no association between any BC treatment and stroke
(data not shown). As the cases were significantly older than the
controls, we adjusted the ORs for age. The overall OR for RT did
not differ significantly from unity. However, as the analyses were
stratified on RT type, differences emerged. Radiotherapy, except
IMC/SCL compared with that of no RT was associated with a lower
risk of stroke. Moreover, RT to IMC/SCL vs that of no RT was
associated with a higher, although not significant, risk of stroke
(OR¼1.3; CI¼0.8–2.2). When pooling the groups, no RT and RT,
except IMC/SCL, a post hoc comparison of RT to IMC/SCL vs the
Table 2 Subjects characteristics
Cases (n¼282) Controls (n¼282)
Year of BC diagnosis
1970–1974 42 (14.9) 34 (12.1)
1975–1979 47 (16.7) 39 (13.8)
1980–1984 53 (18.8) 49 (17.4)
1985–1989 56 (19.9) 56 (19.9)
1990–1994 47 (16.7) 50 (17.7)
1995–2003 37 (13.1) 54 (19.1)
Years of follow-up
o2 50 (17.7) 78 (27.7)
2–5 67 (23.8) 56 (19.9)
5–10 81 (28.7) 87 (30.9)
10–20 61 (21.6) 54 (19.1)
20+ 23 (8.2) 7 (2.5)
Age at BC diagnosis (years)
o60 40 (14.2) 148 (52.5)
60–69 65 (23.0) 68 (24.1)
70–79 113 (40.1) 44 (15.6)
80+ 64 (22.7) 22 (7.8)
T-stage
T1 143 (50.7) 163 (57.8)
T2 79 (28.0) 59 (20.9)
T3–4 13 (4.6) 21 (7.4)
Tx 47 (16.7) 39 (13.8)
N-stage
N0 167 (59.2) 200 (70.9)
N+ 71 (25.2) 59 (20.9)
Nx 44 (15.6) 23 (8.2)
M-stage
M0 280 (99.3) 280 (99.3)
M1 2 (0.7) 2 (0.7)
Stage
I 94 (33.3) 128 (45.4)
II 92 (32.6) 82 (29.1)
III 14 (5.0) 12 (4.3)
IV 2 (0.7) 2 (0.7)
Missing 80 (28.4) 58 (20.6)
BC-side
Right 148 (52.5) 147 (52.1)
Left 134 (47.5) 135 (47.9)
Distant metastasis before stroke
No 259 (91.8) 266 (94.3)
Yes 23 (8.2) 16 (5.7)
Local recurrence before stroke
No LR 272 (96.5) 269 (95.4)
LR 10 (3.5) 13 (4.6)
BC¼breast cancer; LR¼local recurrence.
Table 3 Case characteristics
Cases (n¼282)
Stroke diagnosis
Ischaemic stroke 174 (61.7)
Transient cerebral ischaemia 40 (14.2)
Cerebral infarction 134 (47.5)
Cerebral haemorrhage 29 (10.3)
Subarachnoid haemorrhage 7 (2.5)
Intracerebral haemorrhage 22 (7.8)
Ill-defined cerebrovascular lesion 79 (28.0)
Location of stroke
Carotid right hemisphere 105 (37.2)
Carotid left hemisphere 115 (40.8)
Carotid undefined hemisphere 5 (1.8)
Vertebrobasilar 52 (18.4)
Not defined 1 (0.4)
Insufficient medical records 4 (1.4)
Mode of verification
Computed tomography 206 (73.0)
Autopsy without computed tomography 7 (2.5)
Medical records 65 (23.0)
Insufficient medical records 4 (1.4)
Atrial fibrillation
Yes 63 (22.3)
No 215 (76.2)
Insufficient medical records 4 (1.4)
Breast cancer, radiotherapy and stroke
G Nilsson et al
813
British Journal of Cancer (2009) 100(5), 811–816 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ypooled group showed a significant increase of stroke with an
age-adjusted OR¼1.8 and CI¼1.1–2.8.
We also repeated the analyses stratifying on cerebral haemor-
rhage in one group (n¼29) and ischaemic stroke plus ill-defined
cerebrovascular lesion in another group (n¼253); the latter
showing a same pattern as for all types of stroke, and significantly
increased risk of stroke among the subjects receiving RT to IMC/
SCL vs that of no RT and RT, except IMC and SCL (OR¼1.9;
CI¼1.2–3.2). No significant association between RT and haemor-
rhagic stroke was seen, although the CIs were wide.
Adjuvant tamoxifen was used by few women during the study
period, that is B15% of the subjects, and the associated OR for
stroke was as for chemotherapy below unity, but not in a
statistically significant way.
Tamoxifen was used for either 2 or 5 years. Among the cases,
13/46 had tamoxifen for 2 years, whereas 33/46 had tamoxifen for 5
Table 4 ORs and 95% CIs for stroke and subtypes of stroke associated with adjuvant therapy
Cases Controls Stroke, age adjusted
Cerebral
haemorrhage,
age adjusted
Ischaemic stroke and
ill-defined cerebrovascular
lesion, age adjusted
N (%) N (%) OR 95% CI OR 95% CI OR 95% CI
RT
No 125 (44.3) 91 (32.3) ref ref ref
Yes 157 (55.7) 191 (67.7) 0.85 (0.56, 1.30) 1.39 (0.38, 5.07) 0.79 (0.50, 1.24)
RT
No RT 127 (45.0) 92 (32.6) ref ref ref
RT, except IMC/SCL 58 (20.6) 97 (34.4) 0.45 (0.25, 0.79) 1.52 (0.35, 6.59) 0.34 (0.18, 0.65)
RT to IMC/SCL 97 (34.4) 93 (33.0) 1.32 (0.80, 2.19) 1.23 (0.25, 5.96) 1.33 (0.77, 2.28)
RT
No RT and RT, except IMC/SCL 185 (65.6) 189 (67.0) ref ref ref
RT to IMC/SCL 97 (34.4) 93 (33.0) 1.78 (1.13, 2.82) 1.00 (0.25, 4.01) 1.93 (1.18, 3.17)
Chemotherapy
No 276 (97.9) 261 (92.6) ref ref ref
Yes 6 (2.1) 21 (7.4) 0.69 (0.23, 2.05) 3.58 (0.32, 40.6) 0.26 (0.06, 1.18)
Tam
No 236 (83.7) 239 (84.8) ref ref ref
Yes 46 (16.3) 43 (15.2) 0.69 (0.37, 1.29) 0.16 (0.02, 1.35) 0.94 (0.48, 1.86)
CI¼confidence interval; IMC¼internal mammary chain; OR¼odds ratio; RT¼radiotherapy; SCL¼supraclavicular; Tam¼tamoxifen.
Table 5 Associations between laterality of BC, RT, and location of
stroke
BC-side Carotis right Carotis left P-value
Stroke
Right 49 (43.4) 64 (56.6)
Left 56 (52.3) 51 (47.7) 0.22
RT
Right 25 (43.9) 32 (56.1)
Left 31 (51.7) 29 (48.3) 0.46
RT, except IMC/SCL
Right 9 (45.0) 11 (55.0)
Left 10 (50.0) 10 (50.0) 1.00
RT to IMC/SCL
Right 16 (43.2) 21 (56.8)
Left 21 (53.8) 18 (46.2) 0.37
Ischaemic stroke and ill-defined cerebrovascular lesion
Right 45 (43.7) 58 (56.3)
Left 52 (53.6) 45 (46.4) 0.20
RT
Right 22 (44.9) 27 (55.1)
Left 29 (52.7) 26 (47.3) 0.44
RT, except IMC/SCL
Right 6 (37.5) 10 (62.5)
Left 10 (50.0) 10 (50.0) 0.52
RT to IMC/SCL
Right 16 (48.5) 17 (51.5)
Left 19 (55.9) 15 (44.1) 0.63
BC¼breast cancer; IMC¼internal mammary chain; RT¼radiotherapy;
SCL¼supraclavicular.
Table 6 ORs and 95% CIs for stroke in association with daily fraction
radiation doses
Case Control OR Age adjusted
Daily fraction radiation dose IMC
No RT 184 189 ref
p2.5Gy 20 34 0.56 (0.24, 1.31)
2.6–3.9Gy 64 49 2.61 (1.48, 4.60)
X4Gy 11 10 3.05 (0.97, 9.58)
Unclear 3 0 — —
Daily fraction radiation dose SCL
No RT 183 190 ref
p2.5Gy 19 33 0.54 (0.23, 1.29)
2.6–3.9Gy 45 36 2.14 (1.15, 3.99)
X4Gy 32 23 4.06 (1.85, 8.94)
Unclear 3 0 — —
CI¼confidence interval; IMC¼internal mammary chain; OR¼odds ratio; RT¼
radiotherapy; SCL¼supraclavicular.
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respectively. Only one woman received an adjuvant aromatase
inhibitor.
When investigating laterality, the analysis was restricted to cases
with right or left carotid strokes, but no significant association was
found between the BC laterality, targets of RT, and the location of
the stroke (Table 5).
We further investigated dosage effects of RT, measured by the
daily fraction dose, to different targets and risk of stroke (Table 6).
The RT dosage administered to the remaining breast, after breast
conservation, was standardised with very similar doses for all who
were treated, thus a dose-response relation could not be evaluated
(data not shown). However, for IMC and SCL, there was a
significant trend for higher risk of stroke with increasing daily
fraction dose, especially marked for high doses (X4Gy).
DISCUSSION
The main finding in our study is a statistically significant
(OR¼1.9) increase of stroke among women with BC, who had
received RT to IMC and SCL. The risk was dose dependent and
pertained to ischaemic and ill-defined stroke, but not to
haemorrhagic stroke (although, we caution that the statistical
precision for haemorrhagic stroke is low). There was no increased
risk seen for the RT group as a whole or after exposure to
hormonal treatment or chemotherapy. However, in the studied
time period, few women were recommended for systematic
adjuvant treatments.
This study is based on population-based registries with high
coverage (Mattsson and Wallgren, 1984). This study covers a long
period of follow-up. The medical records could be retrieved for
virtually all cases and controls. We have no reason to believe that
cases and controls were followed differently with respect to
cerebral vascular disease.
The selection of controls followed standard incidence density-
based sampling nested within a well-defined cohort (Rothman,
1998). We deliberately avoided matching for age, stage of disease,
and time period of diagnosis, as indications and methods for RT
are associated with these factors. Indeed, our findings indicate that
such a matching would have entailed over-matching, and the risk
of stroke may have been underestimated. Thus, we aimed to fulfil
one of the basic methodological rules in a case–control study: the
controls will be selected against criteria, which are not associated
with a likelihood of or type of exposure.
Of all the strokes, B90% are ischaemic and 10% are
haemorrhagic (Rothwell et al, 2005). This should also be true
regarding ill-defined stroke. Thus, we deemed it appropriate to
analyse ischaemic and ill-defined stroke together.
Of the cases, 22% had atrial fibrillation at the time of their
stroke, corresponding well to epidemiological studies (Sandercock
et al, 1992). We have no information on cardiovascular risk
factors, such as hypertension, smoking, and hyperlipidaemia at the
time of RT. However, if anything, it is likely that these factors are
associated with more severe co-morbidity and, thus, may be
associated with a contraindication for RT, thereby driving our
estimates to the conservative side. For example, RT, which was not
delivered to IMC and SCL, was associated with a lower risk of
stroke that probably reflects a selection bias. There is no plausible
biological explanation for RT to decrease the risk of stroke. Most
women in this group underwent RT to the remaining breast after
breast conservation; the reasons for avoiding RT after breast
conservation, during this period, include a low-performance status
and serious cardiovascular disease.
Given the possibility of selection bias mentioned above, we
deem it likely that RT not delivered to IMC and SCL is associated
with either low or no risk of stroke. Furthermore, we found no
association between BC laterality and the corresponding hemi-
sphere location of the carotid stroke. Thus, if there is a direct
causal link between RT and stroke, we speculate that it is the dose
to the superior part of the heart and the aortic arch (corresponding
to the IMC radiation field) that is detrimental rather than the dose
to the proximal part of the carotid artery (SCL radiation field). In
that way, IMC radiation would increase the risk of atherosclerosis
(Schultz-Hector and Trott, 2007) and, furthermore, thrombo-
embolic stroke and embolus may follow the blood stream to either
the right or left carotid artery, irrespective of BC laterality and SCL
irradiation. However, we could not analyse the targets, IMC or
SCL, as separate risk factors, as most subjects received RT to both
targets combined. The distribution of stroke location is similar to
that in epidemiological studies (Bamford et al, 1991), neither
supporting, nor making a case against a causal explanation for RT
as a risk factor for stroke.
In contrast to our findings, another study found a significant
association between tamoxifen and stroke, but not between RT to
SCL and stroke (Hooning et al, 2006). However, the subjects were
B20 years younger, and the study group was restricted to 10-year
BC survivors. In two studies (Jagsi et al, 2006; Woodward et al,
2006), there was no association between RT to SCL and stroke, but
no information regarding RT to IMC was given. A recent study
(Woodward et al, 2008) found no increase of carotid stenosis after
radiation, measured by ultrasound.
Our result agrees with another study (Bowers et al, 2005), which
showed a large increase of stroke, Relative Risk¼4.3, among
childhood Hodgkin survivors who had received mantle irradiation,
involving IMC and SCL bilaterally. In keeping with our speculation
that IMC radiation is detrimental, 50% of the Hodgkin survivors
with stroke had concomitant heart or valve problems, predisposing
to cardio-embolic stroke.
High daily fraction radiation doses increase the risk of late
toxicity, such as myocardial infarction (Cuzick et al, 1994), lymph
oedema, and brachial plexopathy (Johansson et al, 2002).
Similarly, we found a dose-dependent relationship between
radiation dose to IMC and SCL and stroke (Table 6). It is difficult
to compare old RT techniques with modern techniques, as
generally hypo fraction was used in the former. When using the
older techniques no dose planning was used, implicating an
increased risk of radiation exposure to other organs in the
mediastinum, namely, the heart and the aortic arch and its
branches. Furthermore, the radiation volumes were larger and the
dose homogeneity was poorer.
Taken together, our earlier finding of a 12% increased risk of
stroke in relative terms after BC diagnosis (Nilsson et al, 2005), the
present target-specific increased risk of a stroke, a dose-response
relationship for daily fraction dose, and a suggestion of an
increased risk of ischaemic stroke, indicate that there may be a
causal relationship between RT to the IMC and SCL and risk of
stroke. Together with other studies, our findings indicate that an
increased risk of stroke has to be taken into consideration in view
of giving RT to IMC or SCL. The ongoing randomised European
Organisation for Research and Treatment of Cancer (EORTC)
study regarding RT to IMC will provide important data regarding
that risk; however, these effects will take a long time to appear.
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